1 / 72

Heart Failure: Evaluation and Treatment Anecita Fadol, PhD, RN,FNP-BC Nurse Practitioner

Heart Failure: Evaluation and Treatment Anecita Fadol, PhD, RN,FNP-BC Nurse Practitioner Department of Cardiology UT MD Anderson Cancer Center. Objectives. Identify the different types of cardiomyopathy Describe the pathophysiologic mechanism of cardiomyopathy/heart failure

nerina
Télécharger la présentation

Heart Failure: Evaluation and Treatment Anecita Fadol, PhD, RN,FNP-BC Nurse Practitioner

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Heart Failure: Evaluation and Treatment Anecita Fadol, PhD, RN,FNP-BC Nurse Practitioner Department of Cardiology UT MD Anderson Cancer Center

  2. Objectives • Identify the different types of cardiomyopathy • Describe the pathophysiologic mechanism of cardiomyopathy/heart failure • Discuss diagnostic testing/procedures for heart failure diagnosis • Discuss the clinical guidelines for the management of heart failure.

  3. Case Examples • A 16 year old male with a history of pneumonia. He was brought to the clinic by his mother because he did not seem to get better after 8 weeks since the initial flu like symptoms. Last night he had severe fatigue and shortness of breath while brushing his teeth. • A 63 year old female with a known history of breast cancer, treated with anthracycline-based chemotherapy 30 years ago. Recently, she noted progressively increasing shortness of breath with exertion, PND and lower extremity swelling.

  4. Cardiomyopathy and Heart Failure • Cardiomyopathy is a weakening or deformity of the heart muscle that causes decreased pumping force. AHA, 2008a; DeMartinis et al, 2003; Hunt et al, 2005; Yahalom et al, 2005

  5. Risk Factors for Cardiomyopathy/HF Major causes of CMP/HF Ischemic heart disease (e.g., coronary artery disease) Nonischemic underlying diseases (e.g., hypertension, valvular heart disease) Risk factors for cardiomyopathy/HF History of or active coronary artery disease Hypertension (75% of patients) Genetic predisposition, congenital heart defects Diabetes Valvular heart disease Thyroid disease Hyperlipidemia Sleep apnea Overweight (elevated body mass index [BMI]) Sedentary lifestyle Advanced age Viral Others (e.g., smoking, alcohol, illicit or therapeutic cardiotoxic drugs) Chang, 2007; DeMartinis et al, 2003; Hunt et al, 2005

  6. Non – ischemic Cardiomyopathy

  7. Heart Failure (HF) Definition A complex clinical syndrome in which the heart is incapable of maintaining a cardiac output adequate to accommodate metabolic requirements and the venous return.

  8. The Donkey Analogy Ventricular dysfunction limits a patient's ability to perform the routine activities of daily living…

  9. Epidemiology of HF in the US • 5 million symptomatic patients in 2001; estimated 10 million in 20371,2 • Incidence: about 550,000 new cases/year2 • Prevalence is 1% between the ages of 50 and 59 years3; progressively increasing to 10% over age 804 12 10 10 8 HF Patients in US (millions) 6 5 3.5 4 2 0 1991 2001 2037 1Adapted from Gilbert E. Rev Cardiovasc Med.2002;3:S42-S47. 2American Heart Association. 2004Heart and Stroke Statistical Update. 2003. 3Ho KKL et al. J Am Coll Cardiol. 1993;22:6A-13A. 4Rich M. J Am Geriatric Soc. 1997;45:968-974.

  10. Part I: Pathophysiology of Heart Failure

  11. Pathological Progression of CV Disease 1 Endothelial Dysfunction CAD CM HTN Valvular Dz Arrhythmia Left ventricularinjury Low ejectionfraction Pathologicremodeling Death Pump failure Chemo Symptoms:DyspneaFatigueEdema • Neurohormonalstimulation • Endothelial dysfunction • Myocardial toxicity • Vasoconstriction • Renal sodium retention Chronicheartfailure 1 Adapted from Cohn JN. N Engl J Med. 1996;335:490–498. 2 He J, Ogden LG, Bazzano LA, et al. Risk Factors for Congestive Heart Failure in US Men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161: 996-1002.

  12. Left Ventricular Dysfunction • Systolic: Impaired contractility/ejection • Approximately two-thirds of heart failure patients have systolic dysfunction1 • Diastolic: Impaired filling/relaxation 30% (EF > 40 %) (EF < 40%) 70% Diastolic Dysfunction Systolic Dysfunction 1 Lilly, L. Pathophysiology of Heart Disease. Second Edition p 200

  13. Classification of HF: Comparison Between ACC/AHA HF Stage and NYHA Functional Class A At high risk for HF but without structural heart disease or symptoms of HF (eg, patients with HTN or CAD) B Structural heart disease but without symptoms of HF I Asymptomatic C Structural heart disease with prior or current symptoms of HF II Symptomatic with moderate exertion III Symptomatic with minimal exertion IV Symptomatic at rest D Refractory HF requiring specialized interventions Asymptomatic ACC/AHA HF Stage1 NYHA Functional Class2 Symptomatic 1Hunt SA et al. J Am Coll Cardiol. 2005;38:2101-2113. 2New York Heart Association/Little Brown and Company, 1964. Adapted from: Farrell MH et al. JAMA. 2002;287:890-897.

  14. Part II:Assessing Heart Failure

  15. Cardiac Assessment A comprehensive cardiac assessment includes the following: Patient history Physical assessment Diagnostic testing

  16. Cardiac Assessment: Diagnostic Testing Initial diagnostic evaluation for HF patient Echocardiogram (ECHO) Measures heart size, wall thickness/mobility, flow gradients, valvular function, LVEF Electrocardiogram Assesses cardiac rhythm, conduction; can detect myocardial infarction, arrhythmias Chest x-ray Detects heart enlargement, fluid around heart or lungs • Standard laboratory tests • Blood chemistry, urinalysis • Complete blood count (CBC) • Renal, liver, thyroid tests • Blood urea nitrogen (BUN), creatinine, albumin (liver function), glucose (diabetes) • CBC detects anemia, infection • Organ function as a contributing factor or resulting from HF Cardiac enzymes Cardiac markers Creatinine kinase (CK, CK-MB), cardiac troponins I and T Brain natriuretic peptide (BNP) • Follow-up: Assess signs and symptoms, functional capacity, body weight, understanding of treatment, compliance, exacerbating factors for HF DeMartinis et al, 2003; Chang, 2007; Fadol, 2006; Hunt et al, 2005

  17. Part III: Current Treatment of Heart Failure

  18. The Vicious Cycle of Heart Failure Management Chronic HF SOB  Weight Diurese & Home Hospitalization MD’s Office IV Lasix or Admit PO Lasix Emergency Room

  19. Goals of Heart Failure Therapy • Relieve heart failure symptoms • Improve overall clinical status • Stabilize acute episodes of decompensation • Decrease morbidity and mortality • Slow and/or reverse disease progression • Identify and treat reversible causes of LV dysfunction

  20. General Approach to Treatment • Determine etiology and/or precipitating factors • Avoid drugs which may aggravate HF • Treat underlying disorders • Anemia, hypo/hyperthyroidism, valvular disease • Revascularization or anti-ischemic therapy in patients with CAD may reduce symptoms of HF • Physical activity (low-intensity) if stable • Restrict fluid (~2 L/day) and sodium intake (<1.5-2 g/day)

  21. Established Therapy:Drugs with a mortalitybenefit in HF • Beta-blockers • Angiotensin converting enzyme (ACE) inhibitors • Angiotensin Receptor Blocker (Candesartan) • Spironolactone or Eplerenone • Isordil/Hydralazine

  22. Digoxin • Mechanism of action: •  contractility • Inhibition of sodium/potassium ATPase pump which acts to increase intracellular sodium-calcium exchange to increase intracellular calcium leading to increased contractility • Neurohormonal • Blunt SNS activation • Increase vagal tone • Slow conduction, prolong AV refractoriness, slowing ventricular response in atrial fibrillation

  23. Pharmacologic Management Digoxin • Enhances inotropy of cardiac muscle • Reduces activation of SNS and RAAS • Controlled trials have shown long-term digoxin therapy: • Reduces symptoms • Increases exercise tolerance • Improves hemodynamics • Decreases risk of HF progression • Reduces hospitalization rates for decompensated HF • Does not improve survival

  24. Digoxin • Warnings/Precautions • Acute myocardial infarction • Acute myocarditis or amyloid cardiomyopathy • Correct electrolyte imbalances • Adjust dose in renal disease • Bradycardia • Withdrawal in CHF patients may lead to recurrent CHF symptoms • Drug interactions • Digoxin toxicity

  25. Digitalis Compounds Like the carrot placed in front of the donkey

  26. Pharmacologic Management Diuretics • Used to relieve fluid retention • Improve exercise tolerance • Facilitate the use of other drugs indicated for heart failure • Patients can be taught to adjust their diuretic dose based on changes in body weight • Electrolyte depletion a frequent complication • Should never be used alone to treat heart failure • Higher doses of diuretics are associated with increased mortality

  27. Diuretics • Diuretics and salt restriction are indicated in patients with current or prior symptoms of HF and reduced LVEF who have evidence of fluid retention (Class I; LOE C) • Use until euvolemic stage is achieved • Continue to prevent recurrence of fluid retention • Increase urinary sodium excretion • Improve pulmonary and peripheral congestion • Decrease preload • No long-term studies • Effects on morbidity and mortality are unknown ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  28. Dosing Oral Diuretics ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  29. Dosing IV Diuretics ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  30. ACE inhibitors • Mechanism of action: •  preload and afterload • Arterial and venous dilatation • Reduces formation of Angiotension II (vasoconstrictor) • Reduces breakdown of bradykinin (vasodilator) • Clinical Effects: • Improve symptoms • Reduce remodeling / progression • Reduce hospitalization • Improve survival

  31. Ace Inhibitors • Recommendations • ACEIs are recommended for all patients with current or prior symptoms of HF and reduced LVEF , unless contraindicated (Class I; LOE A) • ACEIs should be used in all patients with reduced LVEF and no symptoms of HF, even if they have not experienced MI (Class I; LOE A) • ACEIs or ARBs can be beneficial in patients with HTN and LVH and no symptoms of HF (Class IIa; LOE B) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  32. Effect of ACE Inhibitors on Survivalin Heart Failure P=0.30 P<0.0036 P<0.003 Placebo Enalapril Placebo Mortality From All Causes (%) Cumulative Mortality Cumulative Predictability of Death Enalapril Enalapril Hydralazine Isosorbide Dinitrate Months Months Months SOLVD-PSOLVD-T CONSENSUS NYHA Class Class I-II (N=4228) Class II-III (N=2569) Class IV (N=253) Treatment Enalapril Enalapril Enalapril Results 8% 16% 27% (% reduction in all-cause mortality) 1The SOLVD Investigators. N Engl J Med. 1991;325:293-302. 2Cohn J et al. N Engl J Med. 1991;325:303-310. 3The CONSENSUS Trial Study Group. N Engl J Med. 1987;316;1429-1435.

  33. ACE inhibitors ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  34. Contraindications: Hypersensitivity Angioedema related to previous treatment with ACEI Hereditary angioedema Bilateral renal artery stenosis Pregnancy (2nd and 3rd trimester) Warnings/Precautions: Anaphylactic reactions can occur Angioedema can occur at any time during treatment, especially after 1st dose Careful BP monitoring with 1st dose (hypotension) Captopril>Lisinopril>Enalapril May cause hyperkalemia, rise in Scr Ace Inhibitors

  35. Principles of ACEI therapy • Occurrence of ARF should prompt a search for: • Hypotension (MAP <65 mmHg), volume depletion, or nephrotoxin administration • Correct or remove these factors • Consider bilateral renal artery stenosis • ACEIs should be discontinued temporarily while precipitating factors for ARF are corrected • ARBs are not an appropriate substitute under these conditions!!! • ACEI therapy can be reinstituted once these factors are corrected • Hyperkalemia is a potential complication, particularly in patients with DM or CRF • Monitor K+ early after initiation of therapy, reduce dietary K+, avoid agents that aggravate hyperkalemia

  36. ACE inhibitors • Start with a low dose • Increase dose if well tolerated (hold parameters for BP and HR) • Dose NOT determined by symptoms, titrate to target dose • Monitor renal function & serum K+ • Avoid initiating while volume depleted

  37. Diuretics, ACE Inhibitors Reduce the number of sacks on the wagon

  38. ARBs • Recommendations • ARBs approved for the treatment of HF are recommended in patients with current or prior symptoms of HF and reduced LVEF who are ACEI intolerant(Class I; LOE A) • ARBs are reasonable to use as alternatives to ACEIs as 1st line therapy for patients with mild to moderate H F and reduced LVEF, especially for patients already taking ARBs for other indications (Class IIa; LOE A) • The addition of an ARB may be considered in persistently symptomatic patients with reduced LVEF who have already been treated with conventional therapy (Class IIb; LOE B) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  39. ARBs ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  40. Beta-blockers • Recommendations • Beta-blockers and ACEIs should be used in all patients with recent or remote history of MI regardless of EF or presence of HF (Class I: LOE A) • Beta-blockers are indicated in all patients without a history of MI who have reduced LVEF with no HF symptoms(Class I: LOE C) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  41. Pharmacologic Management Beta-Blockers • Cardioprotective effects due to blockade of excessive SNS stimulation • In the short-term, beta blocker decreases myocardial contractility; increase in EF after 1-3 months of use • Long-term, placebo-controlled trials have shown symptomatic improvement in patients treated with certain beta-blockers1 • When combined with conventional HF therapy, beta-blockers reduce the combined risk of morbidity and mortality, or disease progression1 1 Hunt, SA, et al ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult, 2001 p. 20.

  42. Beta-blockers • Mechanism of action: •  Density of ß1 receptors •  Neurohormonalactivation • Slow/reverse ventricular remodeling • Decreased myocyte death from catecholamine- induced necrosis or apoptosis •  HR • Symptomatic worsening of HF • Low doses, slow upward titration • Antiischemic • Antihypertensive • Antiarrhythmic • Antioxidant, Antiproliferatiev

  43. Beta-blockers • Increase EF • Decrease ventricular mass • Reduce systolic and diastolic volumes • Decrease hospitalization and mortality • Greater benefit seen at higher doses

  44. Even low doses of B-blockade can have a dramatic effect Ejection Fraction* ‡ 8 P<.001 † 6 † LVEF (EF units) 4 2 0 Placebo 6.25 mg bid 12.5 mg bid 25 mg bid Carvedilol Patients receiving diuretics, ACE inhibitors, ± digoxin; follow-up 6 months; placebo (n=84), carvedilol (n=261). *Results from the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial (n=345). †P.005 vs placebo. ‡P.0001 vs placebo. Adapted from Bristow MR et al. Circulation. 1996;94:2807–2816.

  45. Effects of Beta-Blockers on Mortality -blocker -blocker -blocker b b b P <0.0001 1.0 1.0 1.0 Placebo Placebo Placebo 0.8 0.8 0.8 Mortality Risk • 34 % Risk Risk • 35 % 34 % ¯ 0.6 0.6 0.6 P=0.006 P<0.00013 0 1 2 Time (years) 0 1 2 0 1 2 CIBIS II MERIT-HF COPERNICUS NYHA Class III-IV (N=2647) II - IV (N=3391) IV (N=2289) Entry criteria LVEF 35% LVEF 40% LVEF  25% Treatment Bisoprolol Metoprolol CR/XL Carvedilol Results 34%34%35% (% reduction in death) 1. CIBIS II Investigators and Committees. Lancet. 1999;353:9-13. 2. MERIT-HF Study Group. Lancet. 1999;353:2001-2007. 3. Packer M et al. N Engl J Med. 2001;344:1651-1658.

  46. Beta-blockers • Recommendations • Beta-blockers and ACEIs should be used in all patients with recent or remote history of MI regardless of EF or presence of HF (Class I: LOE A) • Beta-blockers are indicated in all patients without a history of MI who have reduced LVEF with no HF symptoms(Class I: LOE C) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult http://www.acc.org/clinical/guidelines/failure/hf_index.htm

  47. Beta-blockers

  48. ß-Blockers Limit the donkey’s speed, thus saving energy

  49. Beta-blockers Contraindications: • Cardiogenic shock, symptomatic hypotension • Hypersensitivity • Bradycardia HR<45 • 2nd and 3rd degree heart block; (P-R interval greater than or equal to 0.24 sec) – unless pacemaker places

  50. Beta-blockers Warnings/Precautions: • Anesthesia/surgery (myocardial depression) • Bronchospastic disease (less with cardioselective agents) • Decompensated HF • May mask s/sx hypoglycemia • May mask signs of hyperthyroidism/thyrotoxicosis • PVD – use with caution since may aggravate arterial insufficiency • Avoid abrupt withdrawal (may result in hypertension, tachycardia, ischemia, angina, MI, and sudden death) – discontinue over 1-2 weeks

More Related